# CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions J Med Internet Res 2011;13(4):e126

URL: <u>http://www.jmir.org/2011/4/e126/</u>

doi: 10.2196/jmir.1923 PMID: 22209829

janetperez@udd.cl (non condiviso) Cambia account

🐼 Bozza salvata

\*Campo obbligatorio

Your name \*

First Last

Carola Perez

Primary Affiliation (short), City, Country \* University of Toronto, Toronto, Canada

Universidad del Desarrollo, Santiago, Chile

Your e-mail address \*

abc@gmail.com

janetperez@udd.cl

Title of your manuscript \* Provide the (draft) title of your manuscript.

Effectiveness of an Adjunctive Internet-Based Intervention to Enhance Treatment for Depression in Adults: Randomized Controlled Trial

Name of your App/Software/Intervention \*

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

ASCENSO: "Apoyo, Seguimiento y Cuidado de I

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Second version (intellectual property registrate

Language(s) \*

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Spanish

URL of your Intervention Website or App


e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://www.psyres.de/ascenso/

URL of an image/screenshot (optional)

La tua risposta

Accessibility \* Can an enduser access the intervention presently?



) access only for special usergroups, not open

) access is open to everyone, but requires payment/subscription/in-app purchases

app/intervention no longer accessible

Altro:

### Primary Medical Indication/Disease/Condition \*

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Depression

Primary Outcomes measured in trial \*

comma-separated list of primary outcomes reported in the trial

Depressive symptoms


Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Quality of life; number of appointments and percentage of attended sessions with each one of face to face treatment' professionals: psychiatrist, physician, and/or psychologist

Recommended "Dose" \*

What do the instructions for users say on how often the app should be used?





Approximately Monthly



- ) "as needed"
- Altro: he recommended dose varies according to the intervention componen

Approx. Percentage of Users (starters) still using the app as recommended after 3 months \*

O unknown / not evaluated

0-10%

11-20%

21-30%

31-40%

- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Altro: It was not assessed at 3 months but at 9 months (informations is prese


Overal	I, was the app/intervention effective? *
O ye	s: all primary outcomes were significantly better in intervention group vs control
()	rtly: SOME primary outcomes were significantly better in intervention group vs ntrol
이 no	statistically significant difference between control and intervention
()	tentially harmful: control was significantly better than intervention in one or more tcomes
O inc	conclusive: more research is needed
	ro:

Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
O not submitted yet - in early draft status
onot submitted yet - in late draft status, just before submission
Submitted to a journal but not reviewed yet
Submitted to a journal and after receiving initial reviewer comments
submitted to a journal and accepted, but not published yet
O published
Altro:

### Journal \*

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)





- JMIR Mental Health
- ◯ JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Altro:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *
O Pilot/feasibility
Fully powered
<ul> <li>Manuscript tracking number *</li> <li>If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)</li> <li>on ms number (yet) / not (yet) submitted to / published in JMIR</li> <li>o Altro: JMH ms#26814</li> </ul>
TITLE AND ABSTRACT
1a) TITLE: Identification as a randomized trial in the title
<ul> <li>1a) Does your paper address CONSORT item 1a? *</li> <li>I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")</li> <li>yes</li> </ul>

O Altro:

### 1a-i) Identify the mode of delivery in the title


Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Cano	cella selezione

### Does your paper address subitem 1a-i? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Yes. "Effectiveness of an Adjunctive Internet-based Intervention to Enhance Treatment for Depression in Adults: A Randomized Controlled Trial"



### Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Effectiveness of an Adjunctive Internet-based Intervention to Enhance Treatment for Depression in Adults: A Randomized Controlled Trial"



### Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


"Effectiveness of an Adjunctive Internet-based Intervention to Enhance Treatment for Depression in Adults: A Randomized Controlled Trial"

# 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

# 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




### Does your paper address subitem 1b-i?\*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. ASCENSO platform include psycho-educational information, depressive symptoms monitoring and feedback, and managing emergencies, based on the principles of cognitive behavioral therapy. Emergency management was mental health provider-assisted. TAU includes access to primary care physicians and psychiatrists, to a brief individual psychotherapy, and medication when needed"

### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




### Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Emergency management was mental health provider-assisted"

# 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "A two-arm parallel-group RCT was conducted in an outpatient private mental health care center in Chile". "The baseline questionnaires were administered in-person, and 6- and 9-months assessments were conducted online. The usage of ASCENSO was assessed by server logs"

### 1b-iv) RESULTS section in abstract must contain use data Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it) 1 2 3 4 5 0 $\bigcirc$ $\bigcirc$ $\bigcirc$ $\bigcirc$ subitem not at all important essential Cancella selezione


### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. All informtion in abstract

### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



### Does your paper address subitem 1b-v?


Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The fact that the adjunctive access to ASCENSO did not improve outcome could be due to both the rather high effectiveness of TAU and to patients' limited use of the online platform".

### INTRODUCTION

### 2a) In INTRODUCTION: Scientific background and explanation of rationale

### 2a-i) Problem and the type of system/solution



### Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The high depression prevalence, its complexity and chronicity [6], as well as the low rates of treatment access have led to the design and implementation of comprehensive management strategies for the disorder including interventions based on information and communication technologies [11]." ... "The purpose of the present study was to evaluate the effectiveness of a blended treatment approach, i.e. ASCENSO offered as adjunctive intervention to depression treatment as usual (TAU) for adult patients".

### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Cano	cella selezione

### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "4 recent RCTs have investigated the effectiveness of blended care for depression, with inconsistent results.... It is possible that the lack of consistent results among the mentioned studies is due to the diverse samples (inpatients might have more severe symptoms than outpatients) and different type and duration of the digital intervention programme used.

### 2b) In INTRODUCTION: Specific objectives or hypotheses

### Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The main purpose of the present study was to evaluate the effectiveness of a blended treatment approach, i.e. ASCENSO offered as adjunctive intervention to depression treatment as usual for adult patients, compared to TAU alone."

### METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "This two-arm parallel-group RCT compared standard face-to-face psychotherapy plus medication for patients with depression (TAU) with the blended treatment approach including TAU plus ASCENSO, as a superiority trial." Allocation ratio 1:1; "Randomization was balanced, based on a permutated block design, and stratified by MDD episode (first versus two or more episodes)".

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons


### Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Two modifications were done: a) Only 167 participants were recruited form an initial estimate of 172; b) The exclusion criteria of previous suicide attempt was limited to the past ten years. ("Exclusion criteria were: (a) previous suicide attempt (past 10 years),...; due to the very high rate of this behavior in patients during adolescence). The final criterion is in the article.

### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].



### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

La tua risposta

### 4a) Eligibility criteria for participants

### Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Inclusion criteria: age between 18 and 64 years; clinical diagnosis of current major depressive episode (MDE) by a staff psychiatrist or mental health trained physician; having Internet access. Exclusion criteria: previous suicide attempt (past 10 years); hospitalizations associated with MDD diagnosis; psychotic episodes; bipolar affective disorder; severe cognitive disability; drug abuse or dependence; antisocial, schizotypal, or borderline personality disorder; serious medical illness, and insufficiency in the Spanish language".

### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					Cano	cella selezione

### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

La tua risposta

### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					Cano	cella selezione


### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Patients seeking treatment for depression at a private, university affiliated clinical and research mental health care facility in Santiago, Chile, were invited by a research assistant to join the study (offline recruitment)." "The baseline assessment consisted of web-based self-administered questionnaires that patients completed at a computer provided by the research assistant after they had signed the informed consent". "Follow-up assessments were set by email.

### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

### La tua risposta

### 4b) Settings and locations where the data were collected

### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Patients seeking treatment for depression at a private, university affiliated clinical and research mental health care facility in Santiago, Chile, were invited by a research assistant to join the study (offline recruitment)."

# 4b-i) Report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise. 1 2 3 4 5 subitem not at all important O O O O Image: Cancella selezione


### Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The baseline assessment consisted of web-based self-administered questionnaires that patients completed at a computer provided by the research assistant after they had signed the informed consent. Follow-up assessments consisted of the same web-based self-administered questionnaires but were not completed in the healthcare center. "

### 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)



### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


La tua risposta

# 5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

### 5-i) Mention names, credential, affiliations of the developers, sponsors, and

### owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).



### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes (see information in article).

### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					Cano	cella selezione

### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The ASCENSO acceptability study was carried out prior to the present study (see Espinosa, et al: https://doi.org/10.1089/tmj.2015.0124).

### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
					Cano	cella selezione

### Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

La tua risposta

# 5-iv) Quality assurance methods Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable. 1 2 3 4 5 subitem not at all important O O O O O essential

Does your paper address subitem 5-iv?									
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
La tua risposta									
5-v) Ensure replicability by publishing the source code, and/or providing									
screenshots/screen-capture		•			•	•			
Ensure replicability by publishing the and/or providing flowcharts of the al principle be able to replicate the stud	gorithms ເ	used. Repl	icability (i.	e., other re		•			
	1	2	3	4	5				
subitem not at all important	0	0	۲	0	0	essential			
					Cano	cella selezione			

### Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In the present article a video with aditional material was included (multimedia appendix) showing how the ASCENSO platform looks like. The algorithm used to send messeges and feedback, as well as the platform contents intelectual property are registered (Intelectual property registry, Chile, 2020-A-2967).

### 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The algorithm used to send messeges and feedback, as well as the platform contents intelectual property are registered.

### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
		Cano	cella selezione			


### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Only patients from the health care center included in the present study who were randomly assigned to the EG could have access to the platform. Its use was free. In the article: "Research assistants registered participants of the IG in the ASCENSO platform and gave them a password to access the intervention"

### 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].




### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. See Interventions (in Methods)

### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.




### Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not explicitly. The recommended dose depends on each specific component of ASCENSO; symptoms monitoring should be done every 2 weeks; other components could be used whenever users wanted to.

### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. see ASCENSO description

### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).




### Does your paper address subitem 5-xi?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Every two weeks, patients report the level of their depressive symptoms by completing the PHQ-9 online questionnaire. For this purpose, they receive a link to the questionnaire by e-mail (they can also access it via the online ASCENSO platform). If the participant does not respond, a reminder is automatically sent within 5 days by e-mail".

### 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.



### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Ascenso plaform was used in adjuntion to treatment as usual for despression (TAU). "Research assistants registered participants of the IG in the ASCENSO platform and gave them a password to access the intervention. They also offered information on how to access and use the platform". No other training or support to the patient was done.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed


### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Primary outcome were depressive symptoms as assessed by the Chilean adaptation of the Beck Depression Inventory"; "Secondary outcomes were quality of life, and treatment adherence. Quality of life was measured by the Spanish version of the EuroQol/EQ-5D-3L. It includes a short descriptive questionnaire and a visual analogue scale (EQ VAS)." Both questionnaires were used at baseline, 6- and 9-months".

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].



Copy and paste relevant sections fro						
La tua risposta						
6a-ii) Describe whether and defined/measured/monitore		se" (inclu	uding in <sup>.</sup>	tensity o	of use/do	osage) was
Describe whether and how "use" (inc (logins, logfile analysis, etc.). Use/ad reported in any ehealth trial.	luding inte	-	-			
	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					Cano	cella selezione
Does your paper address sul						
La tua risposta						
•	v, and w	/hen qua	alitative	feedba	ck from	participants
was obtained Describe whether, how, and when qua	alitative fe	edback fro				
6a-iii) Describe whether, how was obtained Describe whether, how, and when qua emails, feedback forms, interviews, f	alitative fe	edback fro				

Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text

La tua risposta

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes were made on the trial outcomes.

### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Cano	cella selezione

### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Considering a medium effect size (d= 0.5), .05 alfa error and .90 of power, a sample size of 140 participants (n=70 each group)"; The final sample size was 172 participants, considering a potential attrition of 20%". More information in the article (see Sample size).

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No interim analysis was considered in the study.

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The randomization allocation sequence was computer-generated and it was sent to the research assistant after the participant signed the Informed Consent"

8b) Type of randomisation; details of any restriction (such as blocking and block size)

### Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Article indicate "Randomization was balanced, based on a permutated block design, and stratified by MDD episode (first versus two or more episodes)." 4 and 6 pemutated blockswere used.

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The randomization allocation sequence was computer-generated and it was sent to the research assistant after the participant signed the Informed Consent". No conceal of sequence was preformed"

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

### Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The research assistant enrolled the participants, an assigned then to the IG or CG following the randomization allocation sequence: "The randomization allocation sequence was computer-generated and it was sent to the research assistant after the participant signed the Informed Consent".

### 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

### 11a-i) Specify who was blinded, and who wasn't Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any). 2 1 3 5 4 $\bigcirc$ $\bigcirc$ $\bigcirc$ subitem not at all important essential Cancella selezione

### Does your paper address subitem 11a-i?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants knew to which study group they belonged. In order to avoid potential bias, physicians and psychotherapists were unaware of the group assignment at the beginning of TAU, but they could access this information if participants decided to disclose this information during sessions (for example, by sharing results of the monitoring). Researchers were also unaware of the group assignment at the time of analyzing the primary and secondary outcomes. However, when analyzing the utilization of the online platform, this information was transparent"

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"							
Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	

### Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

La tua risposta

### 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

### Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant in this study.

## 12a) Statistical methods used to compare groups for primary and secondary

### outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed


### Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Effects on depressive symptoms and quality of life were tested using mixed ANOVA (based on a mixed-models approach) to compare changes from baseline to 6 and 9 months assessments (Time Factor) between the IG and CG (Group\*Time Factor). Additionally, within- and between- group effect sizes were estimated by Cohen's dz and ds respectively [47]."

### 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).



### Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. At baseline IG N=84 and CG=83, "eighty-one percent of the IG and 86% of the CG patients completed 6-months assessment, and 80% of IG and 78% of CG patients completed 9-months assessment". "The primary analysis was based on the intention-to-treat (ITT) principle". More information "Analytical and Statistical Approaches"

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

### Does your paper address CONSORT subitem 12b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Sub-group analysis was no preformed. Adjusted analyzes were not performed since there were no differences between both groups (IG / CG) in the baseline measurement

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)



### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The Ethical Committee of the Mental Health Center Psicomédica Research Group approved the protocol."

### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Cano	cella selezione

### Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Written informed consent was obtaines face to face during recruitment process.

X26-iii) Safety and security p	rocedu	res				
Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)						
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

La tua risposta

### RESULTS

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

### Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study was performed in only one out-patient clinic. Of the 729 eligible patients, 167 met inclusion criteria and were randomized assigned to the IG= 84 and CG= 83). All received the usual treatment as usual, but 5 participants of the IG never entered the ASCENSO platform. Data from all subjects were analyzed in the outcomes assessment (multiple imputation was used).

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study						
This information is in Figure 1 (C	ONSORT	flow dia	gram).			
13b-i) Attrition diagram Strongly recommended: An attrition of intervention/comparator in each grou tables demonstrating usage/dose/en	p plotted	over time,	-			
	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential
					Cano	cella selezione

### Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Figure 1 in the manuscript includes an attrition diagram.

# 14a) Dates defining the periods of recruitment and follow-up

## Does your paper address CONSORT subitem 14a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Recruitment occurred from May-2017 to Febrary-2019". "Follow-up were done at 6-months and after 9-months" from the recruitment (each patient).



### Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant information to report

14b) Why the trial ended or was stopped (early)

## Does your paper address CONSORT subitem 14b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "Recruitment occurred from May-2017 to Febrary-2019, missing 5 subjects to be recruited to reach the estimated sample size. Recruitment was stopped due to study time lines (once 9-months follow-up assessment was completed) and budget constraints."

# 15) A table showing baseline demographic and clinical characteristics for each

#### group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group


## Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 1 shows the demographic and clinical chatacteristics of the intervention and control group (in the manuscript).

# 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.



## Does your paper address subitem 15-i? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Together with general demografic variable self report of internet use and access and percived internet expertice is incluided for each group in the result section (Table 1).

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

# 16-i) Report multiple "denominators" and provide definitions


Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.



### Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 1 reports the number of randomized subjects in the baseline measurement. The analysis of primary and secondary data (Table 2) as estimated using multiple imputation considers - despite the sample loss - the same number of subjects (in the different measurements). Only in the results table that accounts for the usual treatment (TAU, Table 3) different participants were considered according to the type of treatment received in each group.



### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. The primary analysis was based on the intention-to-treat (ITT) principle.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

### Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. See primary and secondary results

# 17a-i) Presentation of process outcomes such as metrics of use and intensity of

#### use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Cano	cella selezione

### Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

# 17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

## Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"at the 9-months follow-up indicated that there were no differences between the groups on dropout rates (P = .07). The dropout rate for face-to-face treatment's component was 54% (45/84) for IG versus 39% (32/83) for CG".

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

### Does your paper address CONSORT subitem 18?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Analysis by sub-group was not carried out.

### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					Cano	cella selezione

Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e	uscript), c	or elaborat	e on this i	tem by pro	oviding add	litional
Sub-analysis comparing only use	ers was r	not prefoi	rmed			
<b>19) All important harms or u</b> (for specific guidance see CONSORT			ects in e	ach gro	up	
	ONSORT	「 subiter	m 19? *			
Does your paper address CC						
Copy and paste relevant sections fro indicate direct quotes from your man	m the mar iuscript), c	or elaborat	e on this i	tem by pro	oviding add	litional
Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e	m the mar iuscript), c explain wh	or elaborat y the item	e on this i is not app	tem by pro blicable/re	oviding add	litional
Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e No adverse effects were identifie	m the man nuscript), c explain wh ed in any	or elaborat y the item of the pa	e on this i is not app articipan	tem by pro blicable/re	oviding add	litional
Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e No adverse effects were identifie 19-i) Include privacy breache Include privacy breaches, technical p but also incidents such as perceived	m the man nuscript), c explain wh ed in any es, techi roblems. or real pri	or elaborat y the item of the pa nical pro This does vacy bread	e on this i is not app articipant oblems not only ir ches [1], te	tem by pro plicable/re ts. nclude phy echnical p	oviding add levant for y rsical "harn roblems, au	litional /our study n" to participants, nd other
Does your paper address CC Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e No adverse effects were identifie 19-i) Include privacy breaches Include privacy breaches, technical p but also incidents such as perceived unexpected/unintended incidents. "U	m the man nuscript), c explain wh ed in any es, techi roblems. or real pri	or elaborat y the item of the pa nical pro This does vacy bread	e on this i is not app articipant oblems not only ir ches [1], te	tem by pro plicable/re ts. nclude phy echnical p	oviding add levant for y rsical "harn roblems, au	litional /our study n" to participants, nd other
Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e No adverse effects were identifie 19-i) Include privacy breache Include privacy breaches, technical p but also incidents such as perceived	m the man suscript), c explain wh ed in any es, techi roblems. <sup>-</sup> or real pri inintendec	or elaborat y the item of the pa nical pro This does vacy bread l effects" a	e on this i is not app articipant oblems not only ir ches [1], te also inclue	tem by pro olicable/re ts. nclude phy echnical p les uninter	oviding add levant for y rsical "harn roblems, au nded positi	litional /our study n" to participants, nd other

# Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no privacy breachs or technical problems that affect participants, to be report.

dback fr	om part	icipants	or obse	ervations	s from
application,	, especially	y if they po	pint to unir	ntended/un	expected effects
1	2	3	4	5	
0	0	0	۲	0	essential
				Cano	cella selezione
	articipants application reasons for	articipants or observa application, especiall reasons for why peop	articipants or observations fron application, especially if they po reasons for why people did or d	articipants or observations from staff/res application, especially if they point to unir reasons for why people did or did not use	$\bigcirc \bigcirc $

### Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This information was not inclueded in the current manuscript but is being adressed in another study that is in process of publication.

# DISCUSSION

# 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

# 22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use). Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use). 1 2 3 4 5 subitem not at all important O O O O O O essential Cancella selezione

# Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The aim of this study was to evaluate the effectiveness of an adjunctive online intervention to enhance face-to-face treatment of patients with depression" "As the results indicated, while both groups showed large within-group effect sizes, the blended approach did not improve the effectiveness of the usual care delivered at the mental health center, in terms of reduction of depressive symptoms or improvement of quality of life"

22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research.						
1	2	3	4	5		
0	0	0	۲	0	essential	
				Cano	cella selezione	
	s, suggest 1	s, suggest future reso 1 2	s, suggest future research.	s, suggest future research. 1 2 3 4	s, suggest future research. 1  2  3  4  5 $\bigcirc  \bigcirc  \bigcirc  \bigcirc  \bigcirc$	

### Does your paper address subitem 22-ii?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. See discussion about qualitative study (for example)

# 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

# 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.




### Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "...limitations, including difficulties for blinding group assignment to patients and medical staff, difficulties for standardizing measurement time (...), the use of self-report scales for clinical variables, and the limited availability of adequate indicators to measure the use"; "limitated generalization to middle-severe depressive patients with low-comorbidities"; "as the face-to-face treatment was carried out in a private health center could bias the sample by excluding people from low SES and those who lack health insurance"; "its limited replicability since it was implemented in the context of routine health care (...)".

# 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial



#### Does your paper address subitem 21-i?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "limitated generalization to middle-severe depressive patients with low-comorbidities"; "its limited replicability since it was implemented in an specific routine health care".

### 21-ii) Discuss if there were elements in the RCT that would be different in a

### routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.



### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

La tua risposta

# OTHER INFORMATION

# 23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"ClinicalTrials.gov NCT03093467"

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24?\*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The full trial protocol is available under request to the corresponding author.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"project was funded by the National Fund for Research and Development in Health FONIS, Grant SA16I0173, and the ANID - Millennium Science Initiative Program / Millennium Institute for Research on Depression and Personality-MIDAP ICS13\_005"

# X27) Conflicts of Interest (not a CONSORT item)

### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Cano	cella selezione


#### Does your paper address subitem X27-i?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Intellectual property of ASCENSO belongs to "Fundación para la Investigación en Depresión y Personalidad, Chile"; "Psychotherapy Research, University Hospital Heidelberg has copyrights of computer source code and software that support ASCENSO platform". "Authors have no other financial and non-financial conflict of interest."

## About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? \*





) no

What were the most important changes you made as a result of using this checklist?
La tua risposta
How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *
100 hours approximately (all changes)
As a result of using this checklist, do you think your manuscript has improved? *
O yes
O no
O Altro: not to much
Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
🔘 yes
o no
O Altro:
Cancella selezione
Any other comments or questions on CONSORT EHEALTH

La tua risposta

# STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

# Final step: Click submit !

Click submit so we have your answers in our database!

Invia

Cancella modulo

Non inviare mai le password tramite Moduli Google.

Questo modulo è stato creato fuori dal tuo dominio. <u>Segnala una violazione</u> - <u>Termini di servizio</u> - <u>Norme sulla</u> <u>privacy</u>

